On February 9, 2015 Aduro Biotech, Inc. reported that it has achieved its first milestone under its collaboration with Janssen Biotech, Inc., by initiating toxicology studies to support an Investigational New Drug Application for ADU-741, an immuno-oncology product candidate for the treatment of prostate cancer (Press release Aduro BioTech, FEB 9, 2015, View Source [SID:1234501616]). The Janssen decision to advance ADU-741 toward clinical trials was based on preclinical data generated in the first eight months of the collaboration. This accomplishment triggered a milestone payment to Aduro.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In May 2014, Aduro entered into an agreement granting Janssen an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under the agreement, facilitated by Johnson & Johnson Innovation, California, Aduro is eligible to receive up to a potential total of $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.

"This is an important validation of our ability to rapidly engineer new product candidates from our LADD platform," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "We are pleased to earn the associated milestone payment and importantly to see our technology progress toward clinical trials to evaluate its utility in prostate cancer."
About LADD

LADD is Aduro’s proprietary platform of live, attenuated, double-deleted Listeria monocytogenes strains that have been engineered to initiate a powerful innate immune response and drive a targeted, durable adaptive immune response.
About ADU-741

ADU-741 is a multivalent LADD product candidate engineered specifically for the treatment of prostate cancer. In May 2014, Janssen Biotech, Inc. licensed exclusive global development and commercialization rights to ADU-741.